centerforbiosimilars

Hillel P. Cohen, PhD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Christina Corridon, MPH, MBA

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Alex Keeton

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Tyler Sandahl, PharmD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Gary Fanjiang, MD, MBA, MS

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

April Breyer Menon, JD

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Peter Pitts

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Free CE Activities

Navigating Outpatient Bispecific Antibody Administration in Lymphoma: Practical Solutions for Community Oncolo ...
centerforbiosimilars

James D. Chambers, PhD, MPharm, MSc

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Travis Brewer

All Things Biosimilars: How Streamlined CES Rules Could Shift the Market ...
centerforbiosimilars

Breaking Down Biosimilar Barriers: The Patent System

Part 1 of this 3-part series for Global Biosimilars Week focuses on legal barriers to biosimilar access in the US, including the patent system, and discusses ongoing legislative efforts to address ...
centerforbiosimilars

The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High

While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more ...